Privacy Policy
Signals Blog

Contributors

Categories

Michael May

Michael May is the President and CEO of CCRM. Michael completed his BASc in Chemical Engineering at the University of Toronto in 1991. He then went on to complete his PhD in Chemical Engineering at the University of Toronto under the supervision of Michael Sefton in 1998. From 2000-2010, Michael was the President, Chief Operating Officer and Co-founder of Rimon Therapeutics Ltd., a Toronto-based regenerative medicine company developing novel medical polymers that possess drug-like activity. Michael sits on a number of Boards and advisory committees and he has coached hockey at the Rep level for over seven years.

Posts by: Michael


10 days ago in Toronto….

The 10-year boom of the cell and gene therapy (CGT) industry has inevitably come to an end: public CGT valuations are way down, companies are settling into cash conservation mode, unrealistic salary demands are being replaced by layoffs, and the vultures circling with $billions in their coffers are patiently waiting for “the feeding frenzy.” Alas, […]

Thinking about longevity makes me feel old

In pondering David Sinclair’s statement “Aging is far more reversible than we thought,” I couldn’t help but reflect on how much our field has changed since I was in grad school. Alas, looking back that far makes me feel really old! My PhD in cell encapsulation focused on diabetes using porcine islets conformally coated in […]

“It was the best of times, it was the worst of times….”

It is difficult to imagine how many times the opening lines to Charles Dickens’ classic A Tale of Two Cities, written over 160 years ago, has been used to describe the world’s current state of affairs. Yet, I am challenged to identify any other time during my lifetime, and most of my parents’, when the […]

Tackling the talent gap in the cell and gene therapy industry

Michael May is President and CEO of CCRM. Peter Zandstra is the Chief Scientific Officer at CCRM and the Founding Director of UBC’s School of Biomedical Engineering. Zandstra and May co-founded CCRM, which launched in June 2011. This article also appears in Biotechnology Focus.  For those of us who have been following and working in the […]

Special op/ed: Canada can lead the world in regenerative medicine — but it won’t happen without strategic investment

Michael May is President and CEO of CCRM, a leader in developing and commercializing regenerative medicine, cell and gene therapy technologies, Michael Rudnicki is Scientific Director and CEO of Stem Cell Network, with a mandate to translate stem cell research into clinical applications, commercial products and public policy, and Peter Zandstra is a professor in […]